10X Genomics Inc (TXG) reported better-than-expected financial results for the third quarter of fiscal 2025, with earnings per share (EPS) of $-0.22, exceeding Wall Street's consensus estimate of $-0.29 by $0.07. Revenue matched expectations at $0.1 billion.
The company, headquartered in Pleasanton, California, is a life science technology firm that develops products to interrogate, understand, and master biology. Its offerings include instruments, consumables, and software for single-cell and spatial biology systems. Notably, the firm’s integrated solutions, powered by the Chromium platform, enable high-throughput analysis of individual biological components.
10X Genomics will host its earnings conference call after market close to discuss these results and provide further insights into its business performance. This update provides insight into the company's operational health, with the results suggesting stronger-than-anticipated fundamentals.
Investors are encouraged to review the full earnings release and listen to management's commentary for complete context on the quarter's performance and outlook. Upcoming earnings are scheduled for May 5, 2026, with an estimated EPS of $-0.2981 and revenue of $0.1 billion, followed by another report on August 4, 2026, with an EPS estimate of $-0.2378 and revenue forecast of $0.2 billion.